Early outcomes of online adaptive MR-guided SBRT for localized prostate cancer: a prospective study
In brief
Online MR-guided SBRT limits grade 2+ urinary toxicity to 3% in prostate cancer
In a prospective cohort, daily adaptive MR-guided stereotactic radiotherapy using 2-mm margins achieved grade 2 or higher urinary side effects in only 3% of patients and no grade 2+ bowel toxicity, with no biochemical failures at one year. Patient-reported urinary, bowel and overall quality of life remained stable, suggesting the adaptive workflow may enhance safety without hydrogel spacers.
- Journal
- Clinical and translational radiation oncology (Q1)
- Published
- 25 July 2026
- Study design
- Cohort / observational study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Abrahams Ocanto, María González, Macarena Teja, Gloria Guardia, Gloria Sánchez, Daniela Gonsalves, et al.
- PMID
- 42569367
- DOI
- 10.1016/j.ctro.2026.101240
Why clinicians should know about it
- Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (paper of the day, 9 August 2026): Prospective MR‑guided SBRT outcomes, directly relevant to RT practice
Abstract
•Online adaptive MR-guided SBRT demonstrated low rates of acute side effects grade ≥ 2 toxicity (3% GU, 0% GI).•Daily adaptive planning with 2-mm margins enabled favorable tolerability outcomes without hydrogel spacers.•Patient-reported outcomes showed minimal impact on urinary, bowel, and global quality of life.•No biochemical failures were observed at 1-year follow-up.•MRgRT may improve safety profiles beyond margin reduction through adaptive workflows.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.